Ben Yong 4

What Happened

• Ben Yong, Chief Medical & Development Officer of BridgeBio Oncology (BBOT), was granted a total of 256,670 award units on March 10, 2026. The filing shows 46,670 restricted stock units (RSUs) and a 210,000-share derivative award; both were granted at $0.00 (no cash purchase). These are grants/awards rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-03-10; Form 4 filed 2026-03-12 (appears timely).
• Grants: 46,670 RSUs (F1) and 210,000 derivative units/options (F2) — total 256,670 units; acquisition price reported $0.00.
• Vesting/settlement:
  • F1 (RSUs): Each RSU converts to one share on vesting; vests in 16 equal quarterly installments over four years beginning January 1, 2026.
  • F2 (derivative): 1/48th of the shares vest and become exercisable in equal monthly installments beginning January 1, 2026 (i.e., 4-year monthly vesting).
• Shares owned after the transactions: Not disclosed in the provided filing excerpt.
• No mention in the filing of a 10b5-1 plan, tax-withholding sale, or immediate sale of shares.

Context

• These entries are grants (compensation) rather than purchases or sales; they do not represent an immediate outlay of cash and will only convert to shares or exercisable options as they vest. For retail investors, such awards are common for executive compensation and do not necessarily indicate a near-term trading signal.